The enormous potential of the ageing market has investors interested. As well as big names in the business of ageing science like Google’s Calico and Craig Venter’s Human Longevity Inc, venture capitalists, pharma and public investment vehicles are backing the sector. Specialist venture capital funds targeting innovation and technology for ageing populations are popping up and according to retirement association AARP, investments have tripled in digital health and wellness for the 50+ market. Yet, ageing research is traditionally an altruistic endeavor taking place in universities and hospitals. How do investors see this paying off? Many have had their fingers burned by high profile biotech flops, and the risk of bad investments is as likely as ever. As a broader pool of investors look to enter the longevity space, what are the scientific anchors they should be searching for in the market? We will hear from a panel of leading investors on what they’re looking for in terms of growth and acquisition strategies in longevity.

Laura Deming, partner, The Longevity Fund
Esther Dyson, executive founder, Way to Wellville
Nick Cherney, senior vice president and head of exchange traded products, Janus Capital Group

Moderator: Alexandra Suich, technology editor, The Economist

свернуть